The online version of this article (doi:10.1186/1476-4598-11-91) contains supplementary material, which is available to authorized users.
Andrea Cavazzoni, Roberta R Alfieri contributed equally to this work.
All authors declare that they have no competing interests.
AC carried out ADCC experiments, interpreted the results and assisted with the draft of the manuscript; DC isolated and cultured NK cells and carried out flow cytometry analysis; FS, LA and PC performed the in vivo studies; PM carried out RT-PCR experiments; MG and MB carried out Western blot analysis; EG performed the statistical analysis, SLM and CF carried out cell growth experiments; FQ, GG and DM carried out immunohistochemical analysis; AM, MT, EB and PGP critically revised the manuscript; AA designed the project and assisted with the draft of the manuscript; RRA, analyzed the results and wrote the manuscript. All authors read and approved the final manuscript.
The epidermal growth factor receptor (EGFR) is an established target for anti-cancer treatment in different tumour types. Two different strategies have been explored to inhibit this pivotal molecule in epithelial cancer development: small molecules TKIs and monoclonal antibodies. ErbB/HER-targeting by monoclonal antibodies such as cetuximab and trastuzumab or tyrosine-kinase inhibitors as gefitinib or erlotinib has been proven effective in the treatment of advanced NSCLC.
In this study we explored the potential of combining either erlotinib with cetuximab or trastuzumab to improve the efficacy of EGFR targeted therapy in EGFR wild-type NSCLC cell lines. Erlotinib treatment was observed to increase EGFR and/or HER2 expression at the plasma membrane level only in NSCLC cell lines sensitive to the drug inducing protein stabilization. The combined treatment had marginal effect on cell proliferation but markedly increased antibody-dependent, NK mediated, cytotoxicity in vitro. Moreover, in the Calu-3 xenograft model, the combination significantly inhibited tumour growth when compared with erlotinib and cetuximab alone.
Our results indicate that erlotinib increases surface expression of EGFR and/or HER2 only in EGFR-TKI sensitive NSCLC cell lines and, in turns, leads to increased susceptibility to ADCC both in vitro and in a xenograft models. The combination of erlotinib with monoclonal antibodies represents a potential strategy to improve the treatment of wild-type EGFR NSCLC patients sensitive to erlotinib.
Authors’ original file for figure 112943_2012_1080_MOESM1_ESM.tiff
Authors’ original file for figure 212943_2012_1080_MOESM2_ESM.tiff
Authors’ original file for figure 312943_2012_1080_MOESM3_ESM.tiff
Authors’ original file for figure 412943_2012_1080_MOESM4_ESM.tiff
Authors’ original file for figure 512943_2012_1080_MOESM5_ESM.tiff
Authors’ original file for figure 612943_2012_1080_MOESM6_ESM.tiff
Authors’ original file for figure 712943_2012_1080_MOESM7_ESM.tiff
Authors’ original file for figure 812943_2012_1080_MOESM8_ESM.tiff
Authors’ original file for figure 912943_2012_1080_MOESM9_ESM.tiff
Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003, 21: 3798-3807. 10.1200/JCO.2003.11.069 CrossRefPubMed
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005, 353: 23-132. 10.1056/NEJMoa043514 CrossRef
Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, Liao ML, Bischoff H, Reck M, Sellers MV: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010, 28: 744-752. 10.1200/JCO.2009.24.3030 CrossRefPubMed
Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, Esteban E, Molinier O, Brugger W, Melezinek I: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010, 11: 521-529. 10.1016/S1470-2045(10)70112-1 CrossRefPubMed
Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009, 373: 1525-1531. 10.1016/S0140-6736(09)60569-9 CrossRefPubMed
Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, Paschold E, Iannotti NO, Dakhil S, Gorton S: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010, 28: 911-917. 10.1200/JCO.2009.21.9618 CrossRefPubMed
Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Storkel S: EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012, 13: 33-42. 10.1016/S1470-2045(11)70318-7 CrossRefPubMed
Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzman M, Rodriguez S, Arribas J, Palacios J, Baselga J: Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res. 2004, 10: 6487-6501. 10.1158/1078-0432.CCR-04-0870 CrossRefPubMed
Janjigian YY, Azzoli CG, Krug LM, Pereira LK, Rizvi NA, Pietanza MC, Kris MG, Ginsberg MS, Pao W, Miller VA, Riely GJ: Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res. 2011, 17: 2521-2527. 10.1158/1078-0432.CCR-10-2662 CrossRefPubMed
Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon Y, Cajal S, Arribas J, Baselga J: Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2009, 28: 803-814. 10.1038/onc.2008.432 CrossRefPubMed
Mimura K, Kono K, Maruyama T, Watanabe M, Izawa S, Shiba S, Mizukami Y, Kawaguchi Y, Inoue M, Kono T: Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines. Int J Cancer. 2011, 129: 2408-2416. 10.1002/ijc.25896 CrossRefPubMed
Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, Carson WE: The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res. 2007, 13: 6419-6428. 10.1158/1078-0432.CCR-07-0865 CrossRefPubMed
Alfieri RR, Galetti M, Tramonti S, Andreoli R, Mozzoni P, Cavazzoni A, Bonelli M, Fumarola C, La Monica S, Galvani E: Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines. Mol Cancer. 2011, 10: 143- 10.1186/1476-4598-10-143 PubMedCentralCrossRefPubMed
Steiner P, Joynes C, Bassi R, Wang S, Tonra JR, Hadari YR, Hicklin DJ: Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin Cancer Res. 2007, 13: 1540-1551. 10.1158/1078-0432.CCR-06-1887 CrossRefPubMed
- Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
Roberta R Alfieri
Silvia La Monica
Pier Giorgio Petronini
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II